Company OXIS International, Inc. Other OTC
Equities
US6918294025
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
08:18pm | Top Midday Decliners | MT |
05:35pm | GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants | MT |
Business Summary
The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 62 | 12/01/21 |
Manu Ohri
DFI | Director of Finance/CFO | 67 | 17/02/22 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 13/12/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 30/04/23 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 10/11/20 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 12/01/21 |
Michael Breen
CEO | Chief Executive Officer | 62 | 12/01/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 96,230 | 0 | 0 | 84.13 % |
Stock B | 1 | 1,416,651 | 1,272,830 ( 89.85 %) | 0 |
Company contact information
GT Biopharma, Inc.
8000 Marina Boulevard Suite 100
94005, Brisbane
+415 919 4040
http://www.gtbiopharma.comSector
1st Jan change | Capi. | |
---|---|---|
+38.22% | 705B | |
+32.82% | 583B | |
-3.75% | 364B | |
+19.80% | 332B | |
+4.89% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+8.83% | 169B |
- Stock Market
- Equities
- GTBP Stock
- Stock
- Company OXIS International, Inc.